- Shen Z-X, Chen G-Q, Ni J-H, Li X-S, Xiong S-M, Qiu Q-Y, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89: 3354-60.
- Soignet SL, Maslak P, Wang Z-G, Jhanwar S, Calteja E, Dardashti LJ, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. New Engl J Med 1998; 339: 1341-8.
- Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L, et al. Use of M-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567-72.
- Chen Z-X, Xue Y-Q, Zhang R, Tao R-F, Xia X-M, Li C, et al. A clinical and experimental study on M-trans retinoic acid-treated acute promyelocytic leukemia patients. Blood 1991; 178: 1413-9.
- White KL, Wiley JS, Frost T, McKendrick JJ, Hermann RP, Seldon M, et al. All-trans retinoic acid in the treatment of acute promyelocytic leukaemia. ANZ J Med 1992; 22: 449-54.
- Bernard J. History of promyelocytic leukaemia. Leukemia 1994; 8: Supp1 2 S1-S5.
- De Thé H, Chomienne C, Lanotte M, Degos L, Dejean A. The t(15; 17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor a gene to a novel transcribed locus. Nature 1990; 347: 558-61.
- Grignani F, Fagioli M, Alcalay M, Longo L, Pandolfi PP, Donti E, et al. Acute promyelocytic leukemia: from genetics to treatment. Blood 1994; 83: 10-25.
- Chen G-Q, Shi X-G, Tang W, Xiong S-M, Zhu J, Cai X, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood 1997; 89: 3345-53.
- Chen G-Q, Zhu J, Shi X-G, Ni J-H, Zhong H-J, Si G-Y, et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3induces NB4 cell apoptosis with downregulation of Bc1-2 expression and modulation of PML-RARa/PML proteins. Blood 1996; 88: 1052-61.
- Wang Z-G, Rivi R, Delva L, Konig A, Scheinberg DA, GambacortiPasserini C, et al. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARa independent manner. Blood 1998; 92: 1497-504.
- Shao W, Fanelli M, Ferrara FF, Riccioni R, Rosenauer A, Davison K, etal. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR protein in acute promyelocytic leukemia cells. J Natl Cancer Inst 1998; 90: 124-33.
- De Botton S, Dombret H, Sanz M, San Miguel J, Caillot D, Zittoun R, et al. Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. Blood 1998; 92: 2712-8.
- Gunz FW. The dread leukemias and the lymphomas: their nature and their prospects. In: Wintrobe MM, editor Blood, pure and eloquent, a story of discovery, of people, and of ideas. New York: McGraw Hill, 1980; Chapter 15.
- Kwong YL, Todd D. Delicious poison: arsenic trioxide for the treatment of leukemia. Blood 1997; 89: 3847-8.
- Huang S-Y, Chang C-S, Jang JL, Tien H-F, Kuo T-L, Huang S-F, et al. Acute and chronic arsenic poisoning associated with treatment of acute promyelocytic leukaemia. Br J Haematol 1998; 103: 1092-5.
- Campbell BG. Mercury, cadmium and arsenic: toxicology and laboratory investigation. Pathology 1999; 31: 17-22.
- Choose new content alerts to be informed about new research of interest to you
- Easy remote access to your institution's subscriptions on any device, from any location
- Save your searches and schedule alerts to send you new results
- Export your search results into a .csv file to support your research